CliffBio
biologic

QIVIGY

Immune Globulin Intravenous, Human-kthm, 10% Solution

Loss of exclusivitySeptember 2037projected — 12-year biologic exclusivity estimate
CompanyKedrion S.p.A. →View the full company profile on CliffBio

Drug detail

Brand nameQIVIGY
Active ingredientImmune Globulin Intravenous, Human-kthm, 10% Solution
Strength5G/50ML
Dosage formSolution
RouteIntravenous
ModalityBiologic
FDA approvalSeptember 2025
Marketing statusRx

More from Kedrion S.p.A.

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

QIVIGY patent cliff — loss of exclusivity September 2037 | CliffBio